Skip links

URVentures News

Fall 2020 TDF Round Now Open!

The Fall 2020 round of the University’s Technology Development Fund (TDF) is now open. The TDF supports UR researchers as they develop their innovations to a more commercial endpoint. Awards are up to $100,000 and support animal testing, prototyping, and other proof-of-concept studies. The fund

Educational Resources Available

Want to further your understanding around IP, entrepreneurship and commercialization? URventures has compiled a list of educational resources to help you get started! We will be routinely updating and adding to this list, and welcome your feedback.

Speedy Action Can Save Vision After An Occipital Stroke

May 27, 2020 Lindsey Valich / A person who has a stroke that causes vision loss is often told there is nothing they can do to improve or regain the vision they have lost. But research from the University of Rochester, published in the journal Brain, may

Spring 2020 TDF Round Cancelled

Given the changing circumstances due to the Covid-19 pandemic, URVentures has decided to cancel the Spring 2020 round of the Technology Development Fund. Please direct any questions to the Fund’s Director. Omar Bakht Fund Director

2020 Medical Device Innovation Challenge

CNY Biotech Accelerator, a division of the State University of New York Upstate Medical University, located in Syracuse, NY, is seeking medical device innovators for its annual 6-month grant-funded Medical Device Innovation Challenge (MDIC). Applications from US-based innovators are accepted January 1 – May 31,

Needle-Free Flu Vaccine Patch Effective in Early Study

A new needle-free flu vaccine patch revved up the immune system much like a traditional flu shot without any negative side effects, according to a study published in the Journal of Investigative Dermatology. Though the research is in the early stages (the patch hasn’t been tested in

New Funding Boosts URMC Biotech Start-Up for Neurological Disorders

Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center (URMC) has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders. The funding represents the largest-ever investment in

VPG Medical featured in Rochester Business Journal

University of Rochester start-up, VPG Medical, was recently featured in the Rochester Business Journal: VPG Medical uses unconventional tech for heart care Among the companies in the Luminate NY accelerator, VPG Medical Inc. is a bit unique. While most companies in the accelerator are based

Handy Gelbard Authors STAT News Piece Touting Multi-Target Drugs

Precision medicine is saving lives, but Harris A. (Handy) Gelbard, director of Center for Neurotherapeutics Discovery at URMC, believes we’re overlooking another class of extremely important treatment candidates: multi-target drugs. In STAT News, he shares his views on why U.S.-based pharmaceutical companies should pay closer attention